Services on Demand
Journal
Article
English (pdf)
Article in xml format
Automatic translationIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista de Saúde Pública
Print version ISSN 0034-8910On-line version ISSN 1518-8787
Abstract
COSTA, Josiane Moreira da et al. Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved. Rev. Saúde Pública [online]. 2019, vol.53, 68. Epub Aug 19, 2019. ISSN 0034-8910. http://dx.doi.org/10.11606/s1518-8787.2019053000879.
OBJECTIVE
To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials.
METHODS
A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II).
RESULTS
The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006–0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003–0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05).
CONCLUSIONS
The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.
Keywords : Anti-Bacterial Agents; Prescription Drug Overuse, legislation & jurisprudence; Drug Resistance, Microbial; Drug Monitoring; Pharmacovigilance.
